On August 1, 2022, the Board of Directors of Avenue Therapeutics, Inc. appointed Alexandra MacLean, M.D., to serve as the Company's Chief Executive Officer, with immediate effect. Dr. MacLean, 55, previously served as Entrepreneur in Residence at Fortress Biotech, Inc., from November 2021 through July 2022. She previously served as General Partner and Principal at TVM Capital GmbH, from January 2020 through October 2021; as Head of Licensing and Business Development at Imbrium Therapeutics L.P., from January 2019 through January 2020; and in various roles at Purdue, from 2015 to January 2019.

Prior to joining Purdue, she served at Plasma Surgical, Inc., from 2014 to 2015, and Covidien, from 2010 to 2013. She began her career in the pharmaceutical industry at Merck & Co., where she worked from 2008 to 2010. Dr. MacLean holds an M.D. degree from Columbia University, Vagelos College of Physicians and Surgeons, an MBA from the University of Colorado Boulder, and an M.Phil.

from the University of Cambridge in History of Science. She obtained a B.Sc. in Physiology from McGill University.

With the appointment of Dr. MacLean as the new Chief Executive Officer, Mr. David Jin will end his term as interim Chief Executive Officer and will continue his responsibilities as Interim Chief Financial Officer and Chief Operating Officer of the Company.